Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
FDA approves Pfizer-BioNTech LP.8.1-adapted monovalent COVID-19 vaccine for high-risk groups
The vaccine is approved for adults aged 65 years and older and individuals aged 5 to 64 years with underlying conditions
Eli Lilly announces Phase 3 ATTAIN-2 trial results for oral GLP-1 agonist orforglipron in obesity…
ATTAIN-2 met primary and key secondary endpoints, with weight loss, A1C reductions, and cardiometabolic improvements at 72 weeks
Dr Reddy’s launches Linaclotide for chronic constipation treatment in India
Dr Reddy’s introduces Colozo, the first guanylate cyclase-C agonist approved in India for adults with chronic idiopathic…
Novartis and BioArctic sign collaboration agreement on BrainTransporter technology for neurological…
Novartis may license drug candidate from collaboration with BioArctic, with potential payments of up to USD 772 million and…
FOPE & PharmaState Academy advance MSME excellence with PULSE session 24 on contract management
Industry leaders underscore the vital role of contract management in ensuring compliance, sustainability, and global…
FOPE & PharmaState Academy’s PULSE Program advances excellence in self-inspection &…
Industry experts highlight how robust self-inspections and quality audits under Revised Schedule M can strengthen GMP compliance…
Industry expert calls for GST parity to support MSMEs and strengthen India’s position as the…
Bhavin Mehta, Vice Chairman of Pharmexcil, highlights how addressing GST inversion challenges through rate alignment and targeted…
GSK introduces Jemperli and Zejula in India to expand oncology portfolio
Jemperli approved for second-line treatment of advanced endometrial cancer; Zejula approved as first-line maintenance monotherapy…
Technology-driven regulatory landscape
Ravi Sharma explains how technology is reshaping regulatory affairs, highlighting the growing role of AI, harmonisation efforts,…
Eris Lifesciences secures ANVISA approval for Ahmedabad manufacturing unit
ANVISA inspection in May 2025 enables Eris Lifesciences’ entry into Brazil’s pharma market